Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "|Years of enrollment" to "|Dates of enrollment")
Line 15: Line 15:
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
!style="width: 33%"|Study
 
!style="width: 33%"|Study
−
!style="width: 33%"|Years of enrollment
+
!style="width: 33%"|Dates of enrollment
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-

Revision as of 18:07, 25 March 2023

Back to Top

1 regimens on this page
1 variants on this page


All lines of therapy

Erlotinib monotherapy

Regimen

Study Dates of enrollment Evidence
Hainsworth et al. 2018 (MyPathway) 2014-2016 Phase 2a, <20 pts in this arm

Biomarker eligibility criteria

  • Gene: EGFR
  • Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
  • Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
  • Biomarker exclusions: EGFR exon 20 mutations

Targeted therapy

Continued indefinitely

References

  1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_solid_neoplasm,_EGFR-mutated&oldid=67169"